GlassScriptPhysician profile
Michele A Catania
NPI 1245599018
$1,458.85
in general payments reported to CMS, 2019-2025
23 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2022: $240 · 2023: $467 · 2024: $283 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $416.73 | 2021-2025 | |
| Inspire Medical Systems, INC. | $260.77 | 2023-2025 | Inspire |
| Novo Nordisk INC | $84.67 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.83 | 2022-2025 | Jardiance |
| Glaxosmithkline, LLC. | $78.95 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Sumitomo Pharma America, INC. | $76.25 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $68.79 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $58.04 | 2021-2024 | Airsupra |
| Lilly USA, LLC | $43.99 | 2021-2024 | Mounjaro, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $34.25 | 2023 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $31.68 | 2022 | |
| Xeris Pharmaceuticals, INC. | $30.15 | 2023 | Gvoke Hypopen |
| Amgen INC. | $29.41 | 2021-2025 | Evenity |
| Radius Health, INC. | $25.12 | 2024 | Tymlos |
| Teva Pharmaceuticals USA, INC. | $20.91 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.11 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $16.93 | 2022 | |
| Daiichi Sankyo INC. | $15.49 | 2021 | |
| Corcept Therapeutics | $15.15 | 2023 | Korlym |
| Astellas Pharma US INC | $13.63 | 2024 | Veozah |
| Abbott Laboratories | $13.32 | 2024 | Freestyle Libre 3 |
| Dexcom, INC. | $13.00 | 2022 | |
| Pfizer INC. | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Catania listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.